Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$840.14

-9.04 (-1.06%)

(As of 12/8/2023 ET)

Today's Range: $839.55
▼
$848.02
50-Day Range: $775.18
▼
$849.18
52-Week Range: $668.00
▼
$853.97

Volume: 374,330 shs
Average Volume: 560,097 shs
Market Capitalization: $91.53 billion

P/E Ratio: 23.96
Dividend Yield: N/A
Price Target: $908.12

Regeneron Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 26 Analyst Ratings

Analysts' Consensus Price Target

$908.12
8.09% Upside

High Forecast	$1,050.00
Average Forecast	$908.12
Low Forecast	$680.00

Type	Current Forecast 12/9/22 to 12/9/23	1 Month Ago 11/9/22 to 11/9/23	3 Months Ago 9/10/22 to 9/10/23	1 Year Ago 12/9/21 to 12/9/22
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	19 Buy rating(s)	20 Buy rating(s)	19 Buy rating(s)	14 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$908.12	$903.64	$903.27	$767.65
Predicted Upside	8.09% Upside	12.71% Upside	14.75% Upside	11.80% Upside

Get Regeneron Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

REGN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Regeneron Pharmaceuticals Stock vs. The Competition

Type	Regeneron Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	8.09% Upside	728.30% Upside	3,819.08% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/6/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$900.00 ➝ $1,000.00	+19.21%
11/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	+17.00%
11/28/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$1,045.00	+31.21%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$800.00	-2.77%
11/3/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$885.00 ➝ $895.00	+9.56%
11/3/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$847.00 ➝ $837.00	+2.62%
Get the Latest News and Ratings for REGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
11/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$915.00 ➝ $914.00	+12.33%
11/3/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$950.00	+16.02%
10/16/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$800.00 ➝ $850.00	+0.70%
9/29/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$665.00 ➝ $680.00	-18.52%
9/15/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$825.00 ➝ $920.00	+10.53%
9/15/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
8/21/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$720.00 ➝ $992.00	+17.25%
8/21/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$960.00 ➝ $985.00	+21.25%
8/21/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$875.00 ➝ $980.00	+20.63%
8/21/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Market Perform	$950.00 ➝ $1,050.00	+29.25%
8/21/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$900.00 ➝ $925.00	+13.86%
7/17/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$935.00 ➝ $900.00	+23.83%
6/28/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
6/28/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/28/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$800.00 ➝ $760.00	+6.13%
5/5/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$976.00 ➝ $895.00	+17.59%
3/31/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight	$900.00 ➝ $950.00	+17.07%
3/28/2023	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
3/27/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$853.00 ➝ $862.00	+14.73%
1/30/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	+17.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:52 PM ET.

REGN Price Target - Frequently Asked Questions

What is Regeneron Pharmaceuticals's consensus rating and price target?: According to the issued ratings of 26 analysts in the last year, the consensus rating for Regeneron Pharmaceuticals stock is Moderate Buy based on the current 1 sell rating, 6 hold ratings and 19 buy ratings for REGN. The average twelve-month price prediction for Regeneron Pharmaceuticals is $908.12 with a high price target of $1,050.00 and a low price target of $680.00. Learn more on REGN's analyst rating history.
Do Wall Street analysts like Regeneron Pharmaceuticals more than its competitors?: Analysts like Regeneron Pharmaceuticals more than other Medical companies. The consensus rating score for Regeneron Pharmaceuticals is 2.69 while the average consensus rating score for medical companies is 2.68. Learn more on how REGN compares to other companies.
Is Regeneron Pharmaceuticals being upgraded by Wall Street analysts?: Over the previous 90 days, Regeneron Pharmaceuticals's stock had 1 upgrade by analysts.

Does Regeneron Pharmaceuticals's stock price have much upside?: According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 12.97% based on their 12-month stock forecasts.
What analysts cover Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals has been rated by Argus, Bank of America, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, TD Cowen, Truist Financial, and Westpark Capital in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:REGN) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial